GLP1R and COVID-19: Nevertheless, GLP-1R agonists may as well be withdrawn from diabetic patients requiring hospitalization with COVID-19, given that their frequent adverse events, gastrointestinal symptoms (e.g., nausea, diarrhea or vomiting) are likely to worsen dehydration and, as a consequence, cause renal failure, which often occur in patients with COVID-19 (27, 53).